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Context: Primary autoimmune hypophysitis (PAH) evolves in most untreated cases in irreversible
hypopituitarism. PAH outcome, instead, after immunosuppressive treatment has not been
completely clarified.
Objective: To evaluate hypophysitis and pituitary function outcomes.
Design: A prospective, double-arm study with a 2-year follow-up.
Setting: Referral center for pituitary disease.
Patients: Twenty PAH cases.
Interventions: Oral prednisone 50 mg/d or conservative strategy by observation.
Main Outcome Measures: Primary endpoint was the improvement/stabilization/worsening of PAH
from baseline to a 2-year visit. Secondary endpoint was the improvement/stabilization/worsening
of pituitary function from baseline to a 2-year visit.
Results: Twelve patients (57.1%) were treated with a glucocorticoid-immunosuppressive therapy,
and eight patients (42.9%) were observed. At the 2-year visit, PAH improvement/recovery
occurred in eight immunosuppressive-treated (66.7%) patients and in two untreated patients
(25%). PAH worsened in three untreated patients (37.5%) and was considered stable in four
immunosuppressive-treated (33.3%) and three untreated patients (37.5%). Improvement/recovery
of pituitary function occurred more frequently in immunosuppressive-treated patients (58.3%)
compared with untreated ones (25%; P = 0.04). Responsiveness to immunosuppressive treatment is
correlated with antipituitary antibody presence (P = 0.01), occurrence of diabetes insipidus at PAH
diagnosis (P = 0.01), absence of the physiological neuropituitary “bright spot” on T1-weighed
images (P = 0.01), and pituitary stalk at optical chiasm larger than 3.9 mm (area under the curve:
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0.97, sensibility: 100%, specificity: 100%; P = 0.04). On the other hand, we failed to identify factors
predicting the outcome, among untreated patients.
Conclusions: Glucocorticoid treatment of hypophysitis improves pituitary secretion and should be
encouraged in accordance with the evaluation of endocrine-, immunological-, and morphological-
predictive markers. (J Clin Endocrinol Metab 103: 3877–3889, 2018)
Primary autoimmune hypophysitis (PAH) is an auto-immune inflammatory disease characterized by an
acute and a subsequent chronic phase. During the acute
phase, the pituitary gland appears enlarged, as a result of
the infiltration of T and B lymphocytes. On the other
hand, a progressive glandular fibrosis typically occurred
during the chronic phase of the disease (1). PAHs are
characterized by secretory pituitary dysfunction, as a
result of a direct and immune-mediated damage of
neuroendocrine cells secreting hormones, rather than
because of an indirect effect as a result of the pituitary
enlargement (2) and the consequent compression or ar-
chitectural distortion of the pituitary stalk and vessels (3,
4). Consequently, in the early stage of the disease, iso-
lated hormone deficit occurredmore frequently (3). In the
later/chronic stage of the disease, instead, an extensive
and irreversible hypopituitarism is described (5, 6),
with a possible evolution in a secondary empty sella
syndrome (7). Frequency of pituitary axis deficit ranged
widely according to different studies, involving;80% to
90% of the cases (8, 14). Despite the increased number of
reported cases, PAH pathogenesis is still poorly un-
derstood. Likewise, the treatment strategies are different
and controversial (15). The PAH treatment should be
focalized on symptoms, replacement of pituitary hor-
monal deficits, and reduction of inflammatory process
(16). PAH treatment should be scheduled according to
the acute or chronic phase of the disease (17). Particu-
larly, in the acute phase, high doses of methylpredniso-
lone, followed by cycles of reduced doses, are suggested
for a lower pituitary enlargement and improvement
of the pituitary function. Different immunosuppressive
agents, as azathioprine, methotrexate, cyclosporine A,
and more recently, rituximab and infliximab, have been
used and proposed in glucocorticoid-resistant cases or in
patients with a major contraindication to glucocorticoid
treatment (14, 16). Pituitary neurosurgery, instead, may
be considered in patients with severe, persisting, or
sudden/rapid progressive neurologic symptoms or mor-
phological signs of compression of nearby structures, as
optical chiasm and nerves of the cavernous sinus (14, 16).
In PAH chronic phase, hormonal replacement therapy is
required for the hypopituitarism. However, PAH out-
come after immunosuppressive treatment is not com-
pletely clarified: pituitary function and morphological
improvements were observed between 15% and 90% of
cases (8–14, 18–20). Treatment outcome seems influ-
enced by pharmacological doses of glucocorticoids, short
standing disease, and diagnosis of diabetes insipidus
(20–22). Currently, the debate on the indication, benefits,
optimal timing, and dosage of glucocorticoids for PAH
treatment remains still open (23), and the therapies of
hypophysitis present several disputes, without available
guidelines or consensus of treatment protocol, according
to the rarity of the disease, the lack of prospective studies,
and the undefined natural history of the disease (24).
Consequently, we aimed to analyze and compare PAH
outcome, among our monocentric series of affected pa-
tients, according to treatment choice (high-dose gluco-
corticoids or clinical observation). At least, we tried to
identify prognostic markers of treatment responsiveness
in glucocorticoid-treated patients and markers of disease
outcome in untreated patients.
Patients and Methods
Study design
Amonocentric, 2-year prospective and cross-sectional study
was conducted on patients affected by PAH. The study was
approved by the Bioethics Committee of the Catholic University
of the Sacred Heart.
Patients
Eligible patients were at least 18 years of age and diagnosed
with PAH. Among our series of PAH-affected patients (2, 11,
25), were consecutively enrolled patients who satisfied all of the
following inclusion criteria:
(1) clinical diagnosis of PAH conducted from November
2008 to April 2015;
(2) immunofluorescence-positive determination of serum
for antipituitary or antihypothalamus autoantibodies
[respectively, antipituitary antibody (APA) and anti-
hypothalamus antibody (AHA)], at PAH diagnosis;
(3) clinical, endocrine, and radiological follow-up (of
at least 2 years) conducted at our Hypothalamic
and Pituitary Disease Outpatient and Radiological
Department.
Key exclusion criteria included debulking pituitary
neurosurgery.
All patients who were enrolled signed a consent form.
Clinical PAH diagnosis and anatomical classification
Clinical diagnosis of hypophysis was made if the following
criteria were satisfied:
3878 Chiloiro et al Hypophysitis Outcome and Prognosis J Clin Endocrinol Metab, October 2018, 103(10):3877–3889
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/article-abstract/103/10/3877/5062269 by Kaohsiung M
edical U
niversity user on 05 O
ctober 2018
(1) occurrence of hypopituitarism and/or hyperprolactinemia
and/or diabetes insipidus and/or visual field deficit and/or
headache;
(2) exclusion of focal hypothalamic-pituitary lesions/masses
(not-secreting and prolactin-secreting pituitary adenomas,
craniopharyngioma, germinoma, meningioma, glioma,
pituitary apoplexy, pituitary and infundibular metastasis,
physiological pituitary hypertrophy, or pituitary hyper-
plasia as a result of primary hormonal deficits);
(3) identification of the typical PAH findings (4) through a
magnetic resonance (MR) as pituitary enlargement in the
absence of intraglandular focal lesions/masses and/or
pituitary stalk swelling with the absence of the poste-
rior pituitary “bright spot” onT1-weighed (T1w) images;
(4) positivity detection of APA or AHA.
The primary autoimmune etiology of hypophysitis was
confirmed after ruling out secondary causes as granulomatous
vasculitis, sarcoidosis, Langerhans cell histiocytosis, and tu-
berculosis, according to diagnostic criteria (8).
PAH cases were anatomically classified (4) through pituitary
MR (pMR) images as the following:
(1) adenohypophysitis (AH) in cases with involvement of
adeno-pituitary (pituitary enlargement) and without
signs of involvement of the neuropituitary gland;
(2) infundibulo-neurohypophysitis (INH) in cases with
signs of the infundibulum, pituitary stalk, and neuro-
pituitary involvement (pituitary stalk thickness and
absence of the posterior pituitary bright spot on T1w
images) without the involvement of the adeno-pituitary;
(3) pan-hypophysitis (PH) in cases of adeno-pituitary,
neuropituitary, pituitary stalk, and infundibulum
involvement.
Baseline endocrine, immunological,
and radiological features
All patients underwent a basal endocrine
test of the pituitary function and when
indicated, a dynamic test, as adrenocorti-
cotropic hormone (ACTH) stimulation
(Synacthen 1 mg eV) and growth hormone-
releasing hormone (GHRH; 1 mg/kg) plus
arginine (0.5 g/kg, until a maximum dosage
of 30 g) tests. Secondary hypothyroidism
was diagnosed according to Jostel thyroid-
stimulating hormone index (26), whereas
diagnosis of secondary hypogonadism was
based on low follicle-stimulating hormone
and testosterone levels in males, absence
of menses in females, and low follicle-
stimulating hormone in postmenopausal
females. Inmost cases, clinical history, along
with the measurement of 24 hours urinary
volume and osmolality during ad libitum
fluid intake, was an indicator of diabetes
insipidus. All patients underwent an APA
and AHA determination, according to a
previous described protocol (11, 25, 27)
(Biosystem, S.A., Barcelona 2010). More-
over, all patients underwent pMR exami-
nations with a 1.5 TMR scanner before and
after the administration of intravenous gadolinium. Pituitary
volume, pituitary stalk thickness (both at pituitary insertion and at
optical chiasma levels), and the physiological posterior pituitary
bright spot on T1w MR images were evaluated in all cases.
Patients’ management and data collection
After PAH diagnosis, patients were proposed with an im-
munosuppressive glucocorticoid treatment (prednisone 50 mg/d)
or conservative management (observation), according to the pi-
tuitary secretory status, age of patients, and clinical conditions, as
summarized in Fig. 1. Glucocorticoid-immunosuppressive treat-
ment was proposed and recommended to (1) young patients
(aged ,60 years), (2) patients suffering from partial or complete
hypopituitarism and diabetes insipidus, and (3) patients who
presented with signs and symptoms of ophthalmological and
neurologic involvement. A conservative approach was specifically
reserved to patients (1) without signs and symptoms of oph-
thalmological and neurologic involvement, (2) with major con-
traindication to glucocorticoid-immunosuppressive treatment,
and (3) with whom the multidisciplinary clinical evaluation of
specific risk/benefit analysis indicated a high risk of adverse events.
In the risk/benefit analysis, the potential adverse effects and
benefits of the high dose glucocorticoid treatment were evaluated,
according to the clinical condition of patients. Hormonal re-
placement treatment with hydrocortisone, levothyroxine, and
desmopressin acetatewas prescribed in the case of pituitary deficit.
All patients underwent a rheumatology evaluation, both at
hypophysitis diagnosis and during follow-up, to evaluate the
concomitant autoimmune disorders and manage the immuno-
suppressive treatments and their potential adverse effects. All
patients were clinically followed up and underwent basal endo-
crine evaluation of pituitary function at 1 and 3 months and then
every 3 months from PAH diagnosis, prescription of hormonal
Figure 1. Flow chart summarizing the indication for glucocorticoid-immunosuppressive
treatment or conservative management follow-up. *Two patients aged .60 y were affected
by congestive heart failure as a result of arterial systemic hypertension, without signs and
symptoms of PAH-related ophthalmological/neurologic involvement. §A single patient was
affected by isolated and slight hyperprolactinemia with a previous history of peptic ulcer
disease and was conservatively managed after a cost-benefit analysis. pts, patients.
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replacement, and/or immunosuppressive treatments. A pMR was
planned at 3months fromPAHdiagnosis and then every 6months
in all patients. An additional pMR was scheduled in cases of
worsening of symptoms and/or pituitary function laboratory tests.
Prednisone dosage was reduced by 50%, 3 months after the
beginning of the treatment, according to the improvement of
neuroradiological signs, and then prednisone dosage was reduced
by 50% every 2 months (treatment duration: 13 months). On the
other hand, in the case of disease progression, prednisone/
azathioprine-associative therapy was prescribed (azathioprine
dosage: 5 mg/kg/die).
After the completion of the immunosuppressive treatment,
endocrine tests were performed at 1 and 3 months and then
every 6 months. A pMR was scheduled after 3 and 6 months
and then annually. According to the prospective design of the
study, clinical and radiological data were collected at the time of
PAH diagnosis and at the 2-year follow-up examination.
Endocrine outcome
With the comparison of baseline endocrine features with
those collected at the 2-year follow-up examination, endocrine
outcome included the following:
(1) resolved in cases of endocrine-deficit resolution, according
to the laboratory features or to the withdrawal of the
hormonal replacement therapies;
(2) improved in cases of endocrine-deficit improvement,
according to laboratory features or to the reduction
of the required dosages of hormonal replacement
therapies;
(3) stable in cases of endocrine feature stabilization,
according to laboratory features or to the maintenance
of required dosages of hormonal replacement therapies;
(4) worsened in cases of endocrine-deficit increase, according
to laboratory features or to the increase of required
dosages of hormonal replacement therapies.
Those patients with a diagnosis of growth hormone defi-
cit (GHD) or secondary hypoadrenalism were retested, re-
spectively, with GHRH plus arginine and ACTH stimulation
tests.
Radiological outcome
Baseline and follow-up neuroradiological features
With the comparison of baseline radiological findings with
those collected at 2-year follow-up examination, the following
radiological outcome was considered:
(1) recovery in the case of reappearance of the physiological
posterior pituitary bright spot on T1w MR images and
in the case of normalization of pituitary volume and
pituitary stalk thickness, according to the value of our
reference ranges;
(2) improvement if at least one of the radiological features
had improved, and none had worsened;
(3) worsening if at least one of the radiological features had
worsened.
Our previous published reference range was established
from 74 consecutive age-matched, healthy subjects (2) and was
compared with those of other authors (28).
Hypophysitis outcome
The following patients were considered:
(1) cured if all of the endocrine and radiological features
had recovered;
(2) improved if at least one of the endocrine or radiological
outcome had improved, and none had worsened;
(3) worsened if at least one of the endocrine or radiological
outcome had worsened.
Statistical analysis
A descriptive analysis was carried out by median and
interquartile ranges (IQRs) for continuous variables and
absolute and relative frequencies for qualitative variables.
Fisher exact test was applied to compare qualitative vari-
ables. The Mann-Whitney and Kruskal-Wallis tests were
performed to compare continuous variables. Nonparametric
tests were applied because of the non-normal distribution of
data. Logistic regression analysis was performed to identify
the factors influencing endocrine and PAH outcomes. To
obtain the optimal threshold of pituitary volume and pitui-
tary stalk diameter values able to predict the PAH radio-
logical improvement, the receiver operating characteristic
analysis was performed. Statistical significance was assumed
when P # 0.05. Data were analyzed using SPSS software,
version 22.
Results
Among 29 patients diagnosed for PAH in our Pituitary
Unit, 20 patients met the inclusion criteria: two patients
were excluded, as they underwent pituitary neurosur-
gery, two patients had a follow-up shorter than 1 year,
and five patients were lost at follow-up. All patients had
at least a 2-year follow-up, a single patient reached a
3-year follow-up, and two patients had a 6-year follow-
up. Thirteen patients are still in follow-up (median du-
ration: 123 IQR: 99 months).
As shown in Fig. 1, eight patients (42.9%) were
managed in a conservatory manner through observation:
two patients refused the glucocorticoid treatment, three
patients carried a major contraindication to high-dose
glucocorticoid treatments (oral candidiasis and un-
stable diabetes mellitus), and three patients were not
treated with an immunosuppressive because of a
multidisciplinary medical decision after a risk-benefit
analysis (two patients over 60 years were affected by
congestive heart failure as a result of arterial systemic
hypertension,without signs and symptoms of PAH-related
ophthalmological/neurologic involvement, and a sin-
gle patient was affected by isolated and slight hyper-
prolactinemia with a previous history of peptic ulcer
disease). Twelve patients (57.1% of cases) were treated
with prednisone. As a result of radiological worsening,
three of the 12 patients (14% of all cases) started
prednisone/azathioprine-associative therapy. At last
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examination, these patients were still considered unre-
sponsive to immunosuppressive treatments. Regarding
patients who had hormonal replacement therapy, eight
were treated with hydrocortisone (in six cases in associ-
ationwith prednisone; median dosage 18.7mg daily; IQR:
16.5), two with Levothyroxine (median dosage: 50 mg
daily; IQR: 0), and six with Desmopressin Acetate (60 mg
table as occurred, median dosage: 60 mg daily).
Clinical features of the study population, according to
the treatment choice, were summarized in Table 1.
Particularly, both APAs and AHAs were detected in 11
patients, only APAs in three patients, and only AHAs in
six patients.
Endocrine outcome
Endocrine outcome of the entire study population and
of the two different treatment groups was summarized in
Tables 2 and 3. At the 2-year follow-up examination,
observing the group of patients affected by hypopitu-
itarism who underwent the immunosuppressive treat-
ment, four cases showed complete recovery of pituitary
function, and improvement of pituitary function was
noted in three patients. Particularly, secondary hypo-
gonadism recovered in all patients, GHD in two patients,
secondary hypoadrenalism and hyperprolactinemia in
one patient, and diabetes insipidus improved in three
cases. Worsening of the pituitary function did not occur
in any of these patients. After the completion of the
immunosuppressive treatment, in no case had the pitu-
itary function worsened.
Among the hypopituitarism-affected patients not treated
with immunosuppressive drugs, hyperprolactinemia re-
covered in a single patient, and secondary hypogonadism
improved in another one. On the other hand, worsening
of pituitary function resulted in three patients, with the
occurrence of secondary hypoadrenalism in all cases and
of secondary hypothyroidism in one case. Endocrine out-
come is correlated to the treatment choice: improvement/
recovery of pituitary function occurred more frequently
in immunosuppressive-treated patients compared with
untreated ones (respectively, 58.3% vs 25%; P = 0.04),
and worsening of pituitary dysfunction occurred only
in patients untreated with immunosuppressive therapy
(Fig. 2).
Radiological outcome
At the 2-year follow-up examination, among the 18
patients with pituitary enlargement, a volume normali-
zation occurred in six patients, improvement in eight
cases, and worsening in four cases.
Pituitary stalk thickness normalized in 11 cases, im-
proved in five cases, and worsened in two cases, among
the 18 patients who at diagnosis had a pituitary stalk
thickening. The physiological posterior pituitary bright
spot on T1w MRIs did not reappear in any cases.
Moreover, a complete recovery of pituitary morphology
occurred in two patients, improvement of radiological
features was demonstrated in 13 cases, and worsening
was in five cases. Among the 12 patients who underwent
immunosuppressive treatment, radiological features im-
proved in eight cases and worsened in four cases. Among
the eight patients untreated with immunosuppressive
drugs, radiological features improved in six cases and
worsened in two cases.
Hypophysitis outcome
At the 2-year follow-up examination, among the 12
patients treated with immunosuppressive drugs, eight im-
proved and were consider to respond to the glucocorticoid
treatment, and four patients did not improve and were
considered resistant to immunosuppressive treatment.
Among the eight patients who did not receive immuno-
suppressive therapy, two cases experienced a spontaneous
hypophysitis improvement, three patients were considered
stable, and three patients progressively worsened.
Adverse events
The adverse events that occurred in the glucocorticoid-
immunosuppressive patients are summarized in Table 4.
No serious adverse event occurred. The most frequent
adverse event was the increase in weight that was
transient and occurred during the first 6 months of
treatment. Likewise, metabolic parameters did not sig-
nificantly change during the treatment period (Table 5).
Other adverse events reported were mild hypokalemia,
transient psychiatric symptoms, and occurrence of in-
fection (flu syndrome in two patients and cystitis in a
single case).
Prognostic factors of hypophysitis outcome
Hypophysitis outcome, according to the treatment
choice, is summarized in Table 6. Sex, age at diagnosis,
antinuclear antibody, anti-extractable nuclear antigen,
and anti-double-stranded DNA autoantibodies did not
correlate to endocrine and hypophysitis outcome, both in
patients treated and untreated with immunosuppressive
therapy.Moreover, among the eight patients who did not
undergo the immunosuppressive therapy, we did not
identify factors predicting endocrine and hypophysitis
outcome. On the other hand, among the 12 patients who
underwent immunosuppressive therapy, it was noted
that the responsiveness to immunosuppressive treatment,
both at univariate and logistic regression analysis (Tables
7 and 8), is correlated with the presence of APA, oc-
currence of diabetes insipidus at PAH diagnosis, absence
of the physiological neuropituitary bright spot on T1w
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Table 1. Baseline Clinical Features of Study Population According to Treatment Choice
Immunosuppressive-
Treated Group
Not Immunosuppressive-
Treated Group P Value
Sex 0.5
Male 3 (50%) 3 (50%)
Female 9 (64.3%) 5 (35.7%)
Race 0.1
White 11 (91.7%) 5 (62.5%)
Not White 1 (8.3%)a 3 (37.5%)b
Median age at diagnosis (IQR) 42 (29) 36 (31.2) 0.9
BMI, kg/m2 (IQR) 24.6 (3) 24.5 (4.2) 0.4
APA, n (%) 0.1
Positivity 10 (71.4%) 4 (28.6%)
Negativity 2 (33.3%) 4 (66.7%)
AHA, n (%) 0.2
Positivity 9 (52.9%) 8 (47.1%)
Negativity 3 (100%) 0
Secondary hypothyroidism, n (%)c 0.1
Yes 0 2 (100%)
No 12 (66.7%) 6 (33.3%)
Secondary hypogonadism, n (%)c 0.3
Yes 5 (71.4%) 2 (28.6%)
No 7 (53.8%) 6 (46.2%)
Secondary hypoadrenalism, n (%)c 0.2
Yes 5 (83.3%) 1 (16.7%)
No 7 (50%) 7 (50%)
GHD, n (%)c 0.5
Yes 2 (50%) 2 (50%)
No 10 (62.5%) 6 (37.5%)
Diabetes insipidus, n (%)c 0.4
Yes 6 (54.5%) 5 (45.5%)
No 6 (66.7%) 3 (33.3%)
Hyperprolactinemia, n (%)c 0.3
Yes 2 (40%) 3 (60%)
No 10 (66.7%) 5 (33.3%)
Anterior hypopituitarism, n (%)c 0.5
Yes 6 (54.5%) 5 (45.5%)
No 6 (66.7%) 3 (33.3%)
Isolated diabetes insipidus, n (%)c 0.2
Yes 0 2 (100%)
No 12 (66.7%) 6 (33.3%
Hypopituitarism and diabetes insipidus, n (%)c 0.1
Yes 4 (100%) 0
No 8 (50%) 8 (50%)
Isolated hyperprolactinemia, n (%)c 0.4
Yes 0 1 (100%)
No 12 (63.2%) 7 (36.8%)
AH, n (%) 5 (62.5%) 3 (37.5%) Ref.
PH, n (%) 2 (66.7%) 1 (33.3%) 0.7
INH, n (%) 5 (55.6%) 4 (44.4%) 0.7
Median pituitary volume, mm3 (IQR)c 528.9 (367.6) 617 (470) 0.29
Median pituitary stalk thickness, mm (IQR)c
At optical chiasm 4.5 (2.3) 4 (1.6) 0.37
At pituitary insertion 2.5 (2) 2.2 (0.9) 0.33
Neuropituitary bright spot, n (%)c 0.6
Present 5 (62.5%) 3 (37.5%)
Absent 7 (58.3%) 5 (41.7%)
Univariate analysis. qualitative variables are reported as absolute value and percent (%). Continuous variables are reported as median 6 IQR.
Abbreviations: BMI, body mass index; Ref, reference.
aEritrean ethnicity.
bEgyptian, Bengali, and Philippine ethnicity.
cEvaluation conducted at PAH diagnosis.
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images, and pituitary stalk at optical chiasm larger than
3.9 mm [area under the curve (AUC): 0.97, sensibility:
87.5%, specificity: 100%; P = 0.01]. Likewise, as shown
in we Tables 7 and 8, we found that the improvement of
pituitary function during follow-up is predicted by the
presence of APA, occurrence at PAH diagnosis of sec-
ondary hypogonadism, diabetes insipidus, PH and INH
anatomical hypophysitis classification, pituitary volume
lower than 493 mm3 (AUC: 0.86, sensibility: 100%,
specificity: 71.4%; P = 0.04), pituitary stalk at optical
chiasm larger than 3.9 mm (AUC: 0.97, sensibility:
100%, specificity: 100%; P = 0.008), and absence of
the physiological posterior pituitary bright spot on
T1w MRIs.
Discussion
In this study, we analyzed PAH outcome in our
monocentric series of affected patients to identify
immunological, clinical, and morphological markers of
immunosuppressive treatment responsiveness. We found
that the occurrence of diabetes insipidus, the absence of
Table 2. Study Population Endocrine Assessment at Baseline and 2-Year Follow-Up
Baseline 2-Year Follow-Up
Secondary hypothyroidism 2/20 3/20
Jostel indexa 1.8 (0.8) 1.8 (0.9)
Jostel indexb 0.94 (2) 1.2 (2)
Secondary hypogonadism 7/20 2/20
Secondary hypoadrenalism 6/20 4/20
Cortisol (mg/dL) after ACTH stimulationb – Cortisol (microgr/dL) after ACTH stimulation b is 12 (5)
Cortisol (mg/dL) after ACTH stimulationc – Cortisol (microgr/dL) after ACTH stimulation c is 24 (2)
Cortisol (mg/dL) after ACTH stimulationd Cortisol (microgr/dL) after ACTH stimulation d is 11 (7)
GHD 4/20 2/20
GH peakb 4.5 (2) 15 (2)e
Diabetes insipidus 11/20 8/20
Plasmatic osmolarity, mOsm/kgb 304 (9) 293 (7)
Urinary osmolarity, mOsm/kgb 40 (23) 254 (345)
Hyperprolactinemia 5/20 3/20
PRL, ng/mLa 16 (13.5) 9 (10.25)
PRL, ng/mLb 24 (2) 11.4 (2)
Qualitative variables are reported as absolute value and percent (%). Continuous variables are reported as median 6 IQR.
Abbreviations: GH, growth hormone; PRL, prolactin.
aValue calculated in entire study population.
bValue calculated in corresponding pituitary dysfunction-affected patients.
cValue referred to the single patient who recovered from secondary hypoadrenalism.
dValue referred to the test performed in the three patients with worsening of ACTH–cortisol axis during the follow-up.
eValue referred to the median value of GH peak at follow-up GHRH plus arginine test of the two patients who recovered from GHD.
Table 3. Endocrine Assessment at Baseline and 2-Year Follow-Up According Treatment Choice
Immunosuppressive-Treated Patients Conservatively Managed Patients
Baseline
2-Year Follow-Up
Baseline
2-Year Follow-Up
Recovered/
Improved Stable
Worse/New
Diagnosis
Recovered/
Improved Stable
Worse/New
Diagnosis
Secondary
hypothyroidism
0 Na Na 0 2 0 2 (66.7%) 1 (33.3%)
Secondary
hypogonadism
5 5 (100%) 0 0 2 1 (50%) 1 (50%) 0
Secondary
hypoadrenalism
5 1 (20%) 4 (80%) 0 1 0 1 (25%) 3 (75%)
GHD 2 2 (100%) 0 0 2 0 2 (100%) 0
Diabetes insipidus 6 3 (50%) 3 (50%) 0 5 0 5 (100%) 0
Hyperprolactinemia 2 1 (50%) 1 (50%) 0 3 1 (33.3%) 2 (66.7%) 0
Qualitative variables are reported as absolute value and percent (%).
Abbreviation: Na, not acceptable.
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the neuropituitary bright spot on T1w MR images, and
the pituitary stalk thickness larger than 3.9 mm played
an important role in building the positive prognostic
markers of hypophysitis and pituitary function im-
provement at follow-up. Moreover, the occurrence of
secondary hypogonadism, as well as pituitary volume
lower than 493 mm3, can predict improvement of pi-
tuitary function at follow-up. As previously demon-
strated (11), an actual study confirms that secondary
hypogonadism and diabetes insipidus, absence of the
neuropituitary bright spot, and pituitary stalk thickness
larger than 3.9 mm are frequently associated with the
diagnosis of PH and INH (Table 9). Likewise, a pituitary
volume lower than 493mm3 is correlated to the diagnosis
of INH (P = 0.002). Consequently, our data suggest that
both the diagnosis of INH or PH and the indirect clinical
and radiological signs of inflammatory involvement of
the pituitary stalk and of neuropituitary (such us the
pituitary stalk thickness and the absence of the neuro-
pituitary bright spot) can positively predict the hypo-
physitis outcome. In fact, according to our results, in
patients treated with immunosuppressive therapy, INH
and PH are associated with a better
prognosis compared with AH cases.
However, although autoimmune eti-
ology of primary hypophysitis has
been widely described, until now, its
pathogenesis is not completely defined,
and it is not predictable if INH, PH,
and AH differ in disease natural his-
tory and treatment responsiveness. In
fact, it is possible to speculate that
INH, AH, and PH should be supported
by different autoantigens, able to
trigger the autoimmune inflammation
(29). However, several proteins have
been suggested as possible PAH anti-
gens, as prohormones and hormones,
nuclear and cytoplasmic enzymes, and
transcriptional factors, all character-
ized by a different pituitary cellular
expression, involving both the neuroendocrine cells and
the T-lymphocytes (30).
Moreover, the different responsiveness to glucocorti-
coid treatment in cases with inflammatory involvement of
pituitary stalk (as INHs and PHs) should be justified by the
different vascular system of the pituitary stalk compared
with the pituitary glands, which should modify the bio-
distribution of the drugs (31). In fact, it was previously
reported that glucocorticoids almost always improve the
swelling of the pituitary and of the pituitary stalk, then
inducing a recovery of the anterior hypopituitarism (32).
Moreover, for the first time, our data suggest a
prognostic and predictive role of APA on the immu-
nosuppressive treatment responsiveness, reinforcing the
hypothesis of the autoimmune inflammation etiology
and pathogenesis of PAH (33). APA positivity can
consequently suggest an activation of the immune system
and an increased sensibility to glucocorticoid treatment.
However, until now, APAs have been considered a
disease marker rather than causative agent (17). If
confirmed on other similar cohorts of patients, use of
APA could therefore guide the treatment decisionmak-
ing. Up until now and based on the experience reported
in the present manuscript, we can consider APA as a
surrogate biomarker of response to treatment.
Prognostic markers of treatment responsiveness were
evaluated in our series among patients treated according to
the same therapeutic protocol. In fact, the three patients
treated with the prednisone/azathioprine-associative ther-
apy were still considered nonresponders to immunosup-
pressive treatments. Moreover, according to our data,
glucocorticoid treatments resulted in usefulness for the
improvement of pituitary function and hypophysitis out-
come. We found a substantial improvement of gonadal
Figure 2. Histogram representing patients’ endocrine outcome according to treatment
choice. Bars indicated patients’ outcome. Fisher test proved a statistically significant high
frequency of worsening of pituitary function among conservatively managed patients
compared with immunosuppressive-treated ones (*P = 0.04).
Table 4. Adverse Events Occurred During
Glucocorticoid Treatment
Patients, n (%)
Transient body weight increase 8 (66.7%)
Transient psychiatric symptoms
(anxiety, nervousness)
3 (25%)
Diabetes mellitus 0
Infections 3 (25%; 2 flu syndromes
and 1 cystitis)
Mild hypokalemia 3 (25%)
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function, GHD, and diabetes insipidus,without occurrence
of adverse events. Our evidences underline the impor-
tance of an etiological-immunosuppressive treatment,
particularly in young, fertile-PAH affected patients with
a long life expectancy. Hypopituitarism, in fact, is a very
serious clinical condition characterized by a highmortality
Table 5. Metabolic Assessment in the 12 Patients Treated With Immunosuppressive Glucocorticoid at
Baseline and During Follow-Up
At Immunosuppressive
Treatment Start
6 Months
Treatment
12 Months
Treatment
24 Months
Follow-Up
BMI, kg/m2 24.6 (3.1) 25.1 (2.4) 24.8 (3.6) 24.4 (2.8)
Fasting blood glucose, mg/dL 77 (19) 73 (23.5) 72 (20) 80 (12.5)
HbA1c, mmol/mol 36 (2.3) 40 (9) 36 (6) 35 (8)
HDL cholesterol, mg/dL 72 (43) 69 (30.7) 67 (52.5) 64 (23.5)
LDL cholesterol, mg/dL 120.5 (48.2) 119.5 (30.2) 120 (37) 117 (63.5)
Triglycerides, mg/dL 139.5 (118.5) 104 (136) 113 (197.5) 117 (89)
Continuous variables are reported as median 6 IQR.
Abbreviations: BMI, body mass index; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Table 6. Factors Predicting Hypophysitis Outcome
Hypophysitis Outcome
Patients on Immunosuppressive
Treatment (12)
Patients Not on Immunosuppressive
Treatment (8)
Responder Nonresponders P Value Improved/Stable Worse P Value
APA, n (%) 0.03 0.5
Positivity 8 (80%) 2 (20%) 3 (75%) 1 (25%)
Negativity 0 2 (100%) 2 (50%) 2 (50%)
AHA, n (%) 0.3 Na
Positivity 5 (55.6%) 4 (44.4%) 5 (62.5%) 3 (37.5%)
Negativity 3 (100%) 0 0 0
Secondary hypothyroidism, n (%)a Na 0.4
Yes 0 0 0 2 (100%)
No 8 (66.7%) 4 (33.3%) 4 (66.7%) 2 (33.3%)
Secondary hypogonadism, n (%)a 0.04 0.7
Yes 5 (100%) 0 1 (50%) 1 (50%)
No 3 (42.9%) 4 (57.1%) 3 (50%) 3 (50%)
Secondary hypoadrenalism, n (%)a 0.6 0.5
Yes 3 (60%) 2 (40%) 1 (100%) 0
No 5 (71.4%) 2 (28.6%) 3 (42.9%) 4 (57.1%)
GHD, n (%)a 0.4 0.7
Yes 2 (100%) 0 1 (50%) 1 (50%)
No 6 (60%) 4 (40%) 3 (50%) 3 (50%)
Diabetes insipidus, n (%)a 0.03 0.5
Yes 6 (100%) 0 2 (40%) 3 (60%)
No 2 (33.3%) 4 (66.7%) 2 (66.7%) 1 (33.3%)
Hyperprolactinemia, n (%)a 0.4 0.5
Yes 2 (100%) 0 1 (33.3%) 2 (66.7%)
No 6 (60%) 4 (40%) 3 (60%) 2 (40%)
AH, n (%) 1 (25%) 4 (75%) Ref. 3 (100%) 0 0.2
PH, n (%) 2 (100%) 0 0.1 0 1 (100%) 0.6
INH, n (%) 5 (100%) 0 0.02 2 (50%) 2 (50%) Ref.
Median pituitary volume, mm3 (IQR)a 422 (487) 631 (309) 0.2 537 (508) 644 (1375) 0.5
Median pituitary stalk thickness,
mm (IQR)a
At optical chiasm 4.9 (2) 3.3 (0.9) 0.02 3.9 (1.8) 4.1 (1.9) 0.5
At pituitary insertion 2.6 (3.3) 2.1 (2.2) 0.4 2.1 (0.7) 2.8 (1) 0.1
Neuropituitary bright spot, n (%)a 0.01 0.2
Present 1 (20%) 4 (80%) 3 (100%) 0
Absent 7 (100%) 0 2 (40%) 3 (60%)
Univariate analysis. Qualitative variables are reported as absolute value and percent (%). Continuous variables are reported as median 6 IQR.
aEvaluation conducted at PAH diagnosis.
doi: 10.1210/jc.2018-01021 https://academic.oup.com/jcem 3885
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/article-abstract/103/10/3877/5062269 by Kaohsiung M
edical U
niversity user on 05 O
ctober 2018
risk and consequently, required an expensive hormonal
replacement therapy (34).
In our group of untreated patients, a spontaneous
recovery of hypophysitis and pituitary function occurred
rarely: in most of cases, hypopituitarism did not change
or worsened during the follow-up stage. However, our
data did not allow us to identify a prognostic marker of
hypophysitis outcome in patients who were not treated
with glucocorticoids.
In previous studies, among patients who underwent
an immunosuppressive treatment, pituitary secretion im-
provement was proven between 15% and 41% and ra-
diological improvement between 36% and 89% of cases
(14, 19, 20, 35). Among patients who did not undergo an
immunosuppressive treatment, instead, the improvement
of pituitary function was reported in 33% (8) and the
spontaneous radiological improvement in 72.7% of cases
(19). This variability is justified by sample size, study
population selection bias, different disease stage, treatment
choice and drug dosage, and definition of the treatment
responsiveness and of the outcome. Moreover, most of
these studies were retrospectively designed. The positive
outcome proven in our series can be explained by an early
hypophysitis diagnosis and initiation of immunosuppres-
sive treatment and the availability of a tertiary referral
center with a medical team devoted to pituitary disease.
Table 7. Factors Predicting Endocrine Outcome
Endocrine Outcome
Patients on Immunosuppressive
Treatment Patients Not on Immunosuppressive Treatment
Resolved/
Improved Stable P Value
Resolved/
Improved Stable Worse P Value (a) P Value (b) P Value (c)
APA, n (%) 0.06 0.7 0.8 0.7
Positivity 7 (70%) 3 (30%) 1 (20%) 2 (40%) 2 (40%)
Negativity 0 2 (100%) 1 (33.3%) 1 (33.3%) 1 (33.3%)
AHA positivity, n (%) 5 (41.7%) 7 (58.3%) Na 2 (25%) 3 (37.5%) 3 (37.5%) Na Na Na
Secondary hypothyroidism,
n (%)a
Na 0.6 0.8 0.6
Yes 0 0 0 1 (50%) 1 (50%)
No 7 (58.3%) 5 (41.7%) 2 (33.3%) 2 (33.3%) 2 (33.3%)
Secondary hypogonadism,
n (%)a
0.03 0.4 0.5 0.7
Yes 2 (28.6%) 5 (71.4%) 1 (16.7%) 3 (50%) 2 (33.3%)
No 5 (100%) 0 1 (50%) 0 1 (50%)
Secondary hypoadrenalism,
n (%)a
0.3 0.6 0.5 Na
Yes 2 (40%) 3 (60%) 0 1 (100%) 0
No 5 (71.4%) 2 (28.6%) 2 (28.6%) 2 (28.6%) 3 (42.9%)
GHD, n (%)a 0.3 0.4 0.5 0.7
Yes 2 (100%) 0 1 (50%) 0 1 (50%)
No 5 (50%) 5 (50%) 1 (16.7%) 3 (50%) 2 (33.3%)
Diabetes insipidus, n (%)a 0.008 0.7 0.2 0.4
Yes 6 (100%) 0 1 (20%) 1 (20%) 3 (60%)
No 1 (16.7%) 5 (83.3%) 1 (33.3%) 2 (66.7%) 0
Hyperprolactinemia, n (%)a 0.3 0.4 0.2 0.7
Yes 2 (100%) 0 1 (33.3%) 0 2 (66.7%)
No 5 (50%) 5 (50%) 1 (20%) 3 (60%) 1 (20%)
AH, n (%) 0 5 (100%) Ref. 1 (33.3%) 2 (66.7%) 0 Ref. Ref. Ref.
PH, n (%) 2 (100%) 0 0.05 0 0 1 (100%) Na Na Na
INH, n (%) 5 (100%) 0 0.004 1 (25%) 1 (25%) 2 (50%) 0.5 0.1 0.5
Median pituitary volume,
mm3 (IQR)a
358.9 (467) 705 (300) 0.04 607 (2) 678 (2) 557 (2) 0.6 0.4 0.7
Median pituitary stalk
thickness, mm (IQR)a
5 (1.4) 3.5 (0.75) 0.005 3.9 (2) 3.8 (2) 4.4 (2) 0.9 0.5 0.7
At optical chiasm 2.3 (3.9) 2.6 (1.95) 0.5 2.2 (2) 2 (2) 3.1 (2) 0.6 0.1 0.3
At pituitary insertion
Neuropituitary bright spot,
n (%)a
0.001 0.5 0.1 0.4
Present 0 5 (100%) 1 (33.3%) 2 (66.7%) 0
Absent 7 (100%) 0 1 (20%) 1 (20%) 3 (60%)
Univariate analysis. Qualitative variables are reported as absolute value and percent (%). Continuous variables are reported as median6 IQR. P value (a),
compared the group of patients with resolved pituitary dysfunction with patients with stable endocrine assessment; P value (b), compared the group of
patients with stable endocrine assessment with those with worsened pituitary endocrine function; P value (c), compared the group of patients with
improved/resolved endocrine assessment with those with worsened pituitary endocrine function.
aEvaluation conducted at PAH diagnosis.
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According to previous literature, the role of surgery in
treatment of hypophysitis is limited to selected cases, such
as those with diagnosis in doubt or those with a rapid/
sudden progression of neurologic symptoms (20). In fact,
although some authors suggested that pituitary neuro-
surgery may improve PAH morphologically (19), the
same does not allow the improvement of pituitary
function. Immunosuppressive treatment with pharma-
cological doses of glucocorticoid is considered ideal
compared with pituitary surgery and conservative man-
agement (clinical observation) for restoring pituitary
secretory function (8, 20). Likewise, in our two patients
who underwent debulking pituitary neurosurgery for the
worsening of the neurologic symptom (11), we did not
obtain a pituitary secretory improvement. However,
according to the different treatment and to the well-
defined postsurgery pituitary region anatomical modi-
fications, we decided to exclude these two patients in the
current study.
In our series, PAH recurrence did not take place.
However, data of hypophysitis recurrence after immu-
nosuppressive treatment are variable in previous reports,
ranging from 18% to 40% (14, 19, 20). These data can
be influenced by the glucocorticoids dosage and treat-
ment period. In our series, duration of glucocorticoid
treatment was at least 13 months, according to a slow
Table 8. Factors Predicting Hypophysitis and Endocrine Outcome
Hypophysitis Worsening
at Follow-Up
Worsening of Pituitary Function
at Follow-Up
APA positivitya P value: 0.01 P value: 0.05
OR: 5 OR: 3.3
95% CI: 1.4–17.3 95% CI: 1.3–8.6
Secondary hypogonadisma P value: 0.09 P value: 0.03
OR: 0.4 OR: 0.3
95% CI: 0.2–1 95% CI: 0.09–0.9
Diabetes insipidusa P value: 0.01 P value: 0.002
OR: 0.3 OR: 0.2
95% CI: 0.1–1 95% CI: 0.02–0.9
Absence of neuropituitary bright spot P value: 0.01 P value: 0.002
OR: 4 OR: 0.3
95% CI: 0.7–21.8 95% CI: 0.1–0.9
Pituitary volume ,493 mm3a P value: 0.09 P value: 0.03
OR: 2.3 OR: 3.5
95% CI: 1–5.5 95% CI: 1.1–11.3
Pituitary stalk at optical chiasm .3.9 mma P value: 0.04 P value: 0.01
OR: 0.3 OR: 0.2
95% CI: 0.1–1 95% CI: 0.02–0.9
PH diagnosis P value: 0.8 P value: 0.01
OR: 0.2 OR: Na
95% CI: 0.03–1.2 95% CI: Na
INH diagnosis P value: 0.09 P value: 0.03
OR: 0.4 OR: 0.3
95% CI: 0.2–1 95% CI: 0.1–0.9
Logistic regression.
aEvaluation conducted at PAH diagnosis.
Table 9. Prognostic Factors Predicting Hypophysitis and Endocrine Outcome, According to Anatomical
Hypophysitis Classification
AH PH INH
P value
AH vs PH
P value
AH vs INH
P value
PH vs INH
Secondary hypogonadisma 0 1 (16.7%) 5 (83.3%) 0.3 0.01 0.3
Diabetes insipidusa 0 3 (27.3%) 8 (72.7%) 0.08 ,0.001 Na
Absence of neuropituitary bright spota 0 3 (25%) 9 (75%) 0.08 ,0.001 Na
Pituitary stalk at optical chiasma .3.9 mma 0 2 (22.2%) 7 (77.8%) 0.02 ,0.001 0.3
Pituitary volume ,493 mm3a 0 0 6 (100%) Na 0.002 0.002
Univariate analysis. Qualitative variables are reported as absolute value and percent (%).
aEvaluation conducted at PAH diagnosis.
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reduction of glucocorticoid pharmacological dosage. In
fact, treatment with glucocorticoid can reduce the in-
flammatory edema in an early phase of the disease and
prevent the development of a chronic inflammation and
related fibrotic process in a later disease stage (36).
The main limitations of our paper are the following:
(1) the small size of the study population, (2) the low
frequency of the histopathological diagnosis of PAH, and
(3) the nonrandomized study design. Our study cohort
was chosen with the application of a very strict inclusion
criteria, to select a homogeneous study group of patients
diagnosed, treated, and followed up according to a
univocal protocol, by a unique medical team devoted to
pituitary disease (namely, the Pituitary Board). However,
our study cohort results are very similar to those in-
vestigated by other research groups, also reflecting the
reported PAH prevalence.
Moreover, despite the nonrandomized study design,
our paper represents a real-life scenario in which PAHs
were treated with immunosuppressive therapy according
to pituitary secretory status and the age of the patients,
clinical condition, and preference. Nevertheless, our
study was conducted in a cross-sectional and prospective
view in the two groups of patients classified as immu-
nosuppressive treated and untreated without differences
of baseline disease aspects.
Although our data should be confirmed on larger
patient series, our actual evidences suggest that hypo-
pituitarism and hypophysitis can improve through
glucocorticoid immunosuppressive administration, par-
ticularly in patients affected by INH and PH. Conse-
quently, according to the evaluation of the risk/benefit
ratio of glucocorticoid-immunosuppressive treatment,
candidate patients should be consequently treated, also
according to the endocrine, immunological, and morpho-
logical potential biomarker of treatment responsiveness.
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